These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33275673)

  • 1. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
    Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of MDS/MPN overlap syndromes.
    Hunter AM; Padron E
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F; Jariwala A; Pullarkat S; Loo E; Liu Y; Tizro P; Ali H; Otoukesh S; Amanam I; Artz A; Ally F; Telatar M; Nakamura R; Marcucci G; Afkhami M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic/myeloproliferative neoplasms.
    Hyjek E; Vardiman JW
    Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
    Kuendgen A; Kasprzak A; Germing U
    Front Oncol; 2021; 11():778741. PubMed ID: 34869027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
    Gerke MB; Christodoulou I; Karantanos T
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
    Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
    Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Clara JA; Sallman DA; Padron E
    Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
    Itzykson R; Fenaux P; Solary E
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Szuber N; Orazi A; Tefferi A
    Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.